Doc's note: Next week, the U.S. begins its new fiscal year. And it's bringing the largest defense budget in U.S. history.

If you've been reading the headlines lately, you know the U.S. is experiencing a serious munitions shortage. While this massive budget should help, as Joel Litman (from our corporate affiliate, Altimetry) explains, the U.S. needs much more than money to replenish its weapons stockpile...

A massive defense budget is colliding with multiyear production delays...

America is on track to spend roughly $1 trillion on military technology this fiscal year. Yet key inventories have reached dangerously low levels.

The shortfall includes the interceptors used to destroy incoming aircraft and missiles, and long-range precision weapons.

Recent military operations in the Middle East have put even more pressure on those reserves.

And replenishing them is a painfully slow process.

Even an immediate funding surge wouldn't close the gap fast enough. The Pentagon would have to wait at least two years before fresh missiles roll off production lines.

The main constraint is physical capacity... There just aren't enough factories and suppliers. There's also a shortage of weapons machinery and skilled labor.

Today, we'll explain how decades of lost industrial capacity created today's munitions shortage and how investors could benefit from a manufacturing rebuild at home.

The U.S. weapons shortage was decades in the making...

The defense drawdown had already begun in the 1980s, as Cold War tensions eased. And the Soviet Union's collapse in 1991 accelerated it.

The Department of Defense ("DOD") budget fell roughly 40%. The Procurement budget took an even bigger hit... dropping 71% in that same period.

America's weapons makers received far fewer orders. Production lines slowed. Suppliers lost business. And factories cut their storage capacity for munitions.

The military head count also shrank alongside the budget. By 1997, active-duty personnel fell roughly one-third below 1988 levels. The DOD budget decreased about 30% over the same period.

Our defense budget is only as useful as our industrial capacity...

Roughly 40% of the Pentagon's spending goes toward new weapons, modernization, and rebuilding low inventories. And as we mentioned, production is the main constraint.

The U.S. spent decades shrinking its defense industry. China, on the other hand, expanded the industrial base behind its military...

China is adding advanced weapons and military equipment at 5 to 6 times the U.S.'s pace. China also has roughly 230 times as much shipbuilding capacity as the U.S. by gross tonnage.

That doesn't mean China produces 230 warships for every one American ship. But it does show how massive China's manufacturing infrastructure is...

And how much work the U.S. needs to do to catch up.

Replenishing our arsenal means rebuilding our defense industry...

The U.S. can't solve its weapons-shortage problem with increased spending alone. It needs a sustained rearmament strategy.

Defense companies require a steady stream of orders to commit to new manufacturing plants. The Pentagon also needs larger inventories... Every new conflict can't immediately cause a production bottleneck.

China has demonstrated its tremendous industrial capacity. And the U.S. is being forced to build the same.

As we restore our arsenal, the entire defense supply chain will feel the effects... from the largest weapons makers to the companies supplying the parts that keep production lines moving.

This presents a good investment opportunity. Be on the lookout for companies that will reshape the defense industry and its supply chain... or be affected by them. These include manufacturers, manufacturing-equipment providers, and the businesses that power that machinery.

Regards,

Joel Litman

Editor's note: On Thursday morning, Joel will explain why President Donald Trump's $1.5 trillion scramble to replenish critical weapons could send a shortlist of little-known defense suppliers soaring by as much as 23-fold in the months ahead.

And if you've missed out on the biggest stocks of the past few years, what Joel and his panel of experts will reveal on September 24 could more than make up for it.

Sign up here to reserve your spot.

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top